The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors

Journal of Rheumatology

Volumn 41, Issue SUPPL. 92, 2014, Pages 15-25

  Wechalekar, Mihir D ^a,b   Vinik, Ophir ^c   Moi, John H Y ^d   Sivera, Francisca ^e   Van Echteld, Irene A A M ^f   Van Durme, Caroline ^g,h   Falzon, Louise ⁱ   Bombardier, Claire ^j,k,l   Carmona, Loreto ^m   Aletaha, Daniel ⁿ   Landewé, Robert B ^o,p   Van Der Heijde, Désirée M F M ^q   Buchbinder, Rachelle ^r,s  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ Department of Medicine   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY HEALTH NETWORK   (Canada)

^l MOUNT SINAI HOSPITAL   (Canada)

^m CAMILO JOSÉ CELA UNIVERSITY   (Spain)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o ACADEMIC MEDICAL CENTER   (Netherlands)

^p Atrium Medical Center   (United States)

^q LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^r CABRINI HOSPITAL   (Australia)

^s MONASH UNIVERSITY   (Australia)

more..

Author keywords

Colchicine; Glucocorticoids; Gouty arthritis; Interleukin 1 inhibitors; NSAID; Paracetamol

Indexed keywords

ANTIGOUT AGENT; COLCHICINE; GLUCOCORTICOID; INTERLEUKIN 1; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE DISEASE; ANTAGONISTS AND INHIBITORS; GOUT; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLCHICINE; GLUCOCORTICOIDS; GOUT; GOUT SUPPRESSANTS; HUMANS; INJECTIONS, INTRA-ARTICULAR; INTERLEUKIN-1; TREATMENT OUTCOME;

EID: 84906871498     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140458     Document Type: Article

References (50)

1. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
2. Neogi T. Gout. N Engl J Med 2011;364:443-52.
3. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med 2011;123 Suppl 1:3-36.
4. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61.
5. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11. (Pubitemid 44641591)
6. Sivera F, Andrés M, Carmona L, Kydd AS, Moi J, Seth R, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014;73:328-35.
7. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout (protocol). Cochrane Database Syst Rev 2012;6:CD009920.
8. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013;4:CD009920.
9. van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev 2014;[in press].
10. van Durme C, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde DM, Landewe RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014;[in press].
11. Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout (protocol). Cochrane Database Syst Rev 2012;7:CD009993.
12. Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev 2014;[in press].
13. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2 [updated September 2009. Internet. Accessed June 2, 2014.]. The Cochrane Collaboration, 2009. Available from: www.cochrane-handbook.org.
14. Sackett DL, Richardson WS, Rosenberg WM, Haynes RB. Evidence based medicine: How to practice and teach EBM. London: Churchill Livingstone; 1997.
15. O'Sullivan JB. Gout in a New England town. A prevalence study in Sudbury, Massachusetts. Ann Rheum Dis 1972;31:166-9.
16. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
17. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5. (Pubitemid 41780667)
18. Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: www.cochrane-handbook.org.
19. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988;31:803-5.
20. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 2008;371:1854-60. (Pubitemid 351736009)
21. Man CY, Cheung ITF, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout-like arthritis: A double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7. (Pubitemid 46601694)
22. Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther 2010;13:R53.
23. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7. (Pubitemid 24234673)
24. So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010;62:3064-76.
25. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
26. Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: A randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013;15:R25.
27. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4. (Pubitemid 18014682)
28. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060-8.
29. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
30. Butler RC, Goddard DH, Higgens CS, Hollingworth P, Pease CT, Stodell MA, et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985;20:511-3. (Pubitemid 16193361)
31. Cheng T-T, Lai H-M, Chiu C-K, Chem Y-C. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406. (Pubitemid 38457332)
32. Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970;10:275-80.
33. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittel Forschung 1983;33:641-3. (Pubitemid 13127047)
34. Garcia de la Torre I. [A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis] (Spanish). Investigacion Medica Internacional 1987;14:92-7.
35. Lederman R. A double-blind comparison of etodolac (Lodine) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344-54.
36. Lomen PL, Turner LF, Lamborn KR, Winblad MA, Sack RL, Brinn EL. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134-9. (Pubitemid 16044387)
37. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
38. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 2004;50:598-606. (Pubitemid 38202232)
39. Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92. (Pubitemid 34666615)
40. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6.
41. Siegmeth W, Placheta P. [Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis] (German). Wiener Klinische Wochenschrift 1976;88:535-7.
42. Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973;32:351-3.
43. Sturge RA, Scott JT, Hamilton EB, Liyanage SP, Dixon AS, Davies J, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis 1977;36:80-2. (Pubitemid 8038411)
44. Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. J Med Assoc Thailand 1985;68:111-6. (Pubitemid 15003099)
45. Valdes EF. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflammation 1987;9:133-6. (Pubitemid 18059081)
46. Weiner GI, White SR, Weitzner RI, Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
47. Willburger RE, Mysler E, Derbot J, Jung T, Thurston H, Kreiss A, et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. Rheumatology 2007;46:1126-32. (Pubitemid 47050616)
48. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993;20:111-3. (Pubitemid 23049192)
49. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F, Burgos-Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial. J Rheumatol 2012;39:1859-66.
50. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology 2007;46:1372-4.